Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for ...

At the ESMO conference, BioCity presented interim Phase 1 clinical ... At this point, we believe the company is well ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

We plan to initiate the trial in Q2 2025 and expect to have data from the interim analysis ... And we were excited to see ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The outcome of the primary endpoint of PFS is projected to be available in the first half of 2025, potentially followed by a BLA submission ... at the 2024 European Society of Medical Oncology (ESMO) ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

"The $9.2 million in cash proceeds received this month from the exercise of existing warrants has strengthened our balance sheet to extend beyond our PDUFA date and into 2025. We are now ... Society ...